[Translated article] Environmental impact of inhaled therapies in a cystic fibrosis unit: Strategies for sustainability
Farmacia Hospitalaria · 2025
DOI: 10.1016/j.farma.2025.02.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Laura Gómez-Ganda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital Universitario Vall'Hebron, Barcelona. Spain. Electronic address: laura.gomez@vallhebron.cat. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: Inhaled therapy is essential in cystic fibrosis; however, inhalers have a significant environmental impact due to the greenhouse gases (GHGs) emitted. The environmental impact of a product is estimated by its carbon footprint (CF). Pressurized metered-dose inhalers (pMDIs) have a higher CF than dry powder inhalers (DPIs) and soft mist inhalers (SMIs) due to the incorporation of GHGs. The objectives are to analyze the consumption of inhalers (β2-adrenergic agonist bronchodilators, anticholinergics, and/or corticosteroids) in a cystic fibrosis unit and estimate the generated CF. METHOD: Retrospective determination (January 2018-December 2023) of consumption and CF (tCO2eq) by type of inhaler was conducted. Consumption and CF trends were evaluated using linear regression. RESULTS: Annually, 1.529 (1.279-1.613) pMDIs, 1.055 (855-1.333) DPIs, and 28 (20-42) SMIs were dispensed, representing 55.97%, 42.33%, and 1.70%, respectively. A statistically significant positive trend in the consumption of SMIs was observed. The median annual CF was: pMDIs 38.3 (31.2-40.3) tCO2eq, DPIs 0.8 (0.6-0.9) tCO2eq, and SMIs 0.02 (0.02-0.03) tCO2eq, representing 97.86%, 2.04%, and 0.10%, respectively. CONCLUSIONS: pMDIs were the inhalers with the highest consumption and CF, although their consumption appears to be decreasing, with an increase in the consumption of SMIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Farmacia, Hospital Universitario Vall'Hebron, Barcelona. Spain. Electronic address: laura.gomez@vallhebron.cat.
- Servicio de Farmacia, Hospital Universitario Vall'Hebron, Barcelona. Spain.
- Servicio de Farmacia, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Spain.
- Facultad de Farmacia, Universidad de Barcelona (UB), Barcelona. Spain.
Zitieren
APA
Gómez-Ganda, L., García-Palop, B., Mariscal-Puig, A., Ábalos-Camacho, A., & Fernández-Polo, A. (2025). [Translated article] Environmental impact of inhaled therapies in a cystic fibrosis unit: Strategies for sustainability. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2025.02.002
Vancouver
Gómez-Ganda L, García-Palop B, Mariscal-Puig A, Ábalos-Camacho A, Fernández-Polo A. [Translated article] Environmental impact of inhaled therapies in a cystic fibrosis unit: Strategies for sustainability. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2025.02.002
BibTeX
@article{GmezGanda2025,
author = {Gómez-Ganda, Laura and García-Palop, Beatriz and Mariscal-Puig, Arnau and Ábalos-Camacho, Alejandro and Fernández-Polo, Aurora},
title = {[Translated article] Environmental impact of inhaled therapies in a cystic fibrosis unit: Strategies for sustainability},
journal = {Farmacia Hospitalaria},
year = {2025},
doi = {10.1016/j.farma.2025.02.002}
}
EUVIMED